Related Experiment Video For Endometrial cancer
Updated: Jul 5, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Impact of Biopsy Diagnostic Methods on the Prognosis of Stage I Endometrioid Cancer
Lucas Helms1, Laura Sabiani2, Sara Djemouai1
1Department of Surgical Gynecology, Conception Hospital, Marseille, France.
Background/Aim:
Endometrial cancer is commonly diagnosed via endometrial biopsy, often performed alongside diagnostic hysteroscopy, a procedure raising concerns about tumor cell dissemination and recurrence, particularly during operative hysteroscopies. The aim of this study was to assess the impact of the diagnostic method on the prognosis of stage I endometrioid cancer.
Patients And Methods:
This retrospective bi-centric study (2010-2019) included patients with stage I endometrioid cancer, categorized into three groups according to the diagnostic method: "Blind Biopsy," "Diagnostic Hysteroscopy," and "Operative Hysteroscopy." The primary endpoints were recurrence or death at three and five years following surgical treatment.
Results:
A total of 169 patients were included; 33 were lost to follow-up at three years. Among the remaining 136, 11 recurrences (8.1%) and six deaths (4.4%) were recorded. The "Operative Hysteroscopy" group had a recurrence rate of 10.4% (7/67), with no significant difference compared to the other groups (p=0.66). Recurrence-free survival at 3 years was 90.6% for the overall population and 89.6% for the "Operative Hysteroscopy" group (p=0.55).
Conclusion:
The biopsy diagnostic methods did not have a significant impact on the 3-year prognosis of patients with stage I endometrioid cancer.
